Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Immunocore Holdings plcNASDAQ: IMCR
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to 12.2%
Net margin was 12.2% in Q1 FY2026, up 6.8 pp from a year earlier. On a trailing-twelve-month basis it was -4.9%, up 1.6 pp year over year. Over 3 fiscal years it widened by 21.3 pp.
Context
- Net margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 11 analysts of 0.6% for the fiscal year ending Dec 2026, up from -8.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 12.2%+40.9 pp QoQ
- Last fiscal yearDec 2025
- -8.9%+7.6 pp YoY
- LTMMar 2026
- -4.9%+1.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.8 pp | +11.0 pp | +4.2 pp |
| 1 year | +7.6 pp | +9.4 pp | +1.9 pp |
| 3 years | +21.3 pp | +12.2 pp | -9.0 pp |
| 5 years | +37.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -8.9%
- Year-over-year change
- +7.6pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -8.9% | +7.6pp |
| FY2024 | 2024-12-31 | -16.5% | — |
| FY2023 | 2023-12-31 | -22.2% | +8.0pp |
| FY2022 | 2022-12-31 | -30.1% | +463.3pp |
| FY2021 | 2021-12-31 | -493.4% | — |
Net Margin vs competitors
How IMCR compares with its peers on the latest reported figures
- IMCR's LTM Mar 2026 net margin of -4.9% is the 2nd highest of the 11 companies compared; the peer median is -458.0%.
- Its year-over-year change of +1.6 pp is the 3rd highest of 11, against a peer median of -79.1 pp.
- Over three fiscal years its change of +21.3 pp compares with a peer median of -4.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 48.0% | +99.2 pp | +497.8 pp | |
| LTM Mar 2026 | -4.9% | +1.6 pp | +21.3 pp | |
| LTM Mar 2026 | -44.8% | -8.2 pp | +29.9 pp | |
| LTM Jun 2026 | -64.0% | -52.0 pp | -94.1 pp | |
| LTM Jun 2026 | -155.6% | -46.5 pp | -39.7 pp | |
| LTM Jun 2026 | -386.3% | -269.5 pp | +95.5 pp | |
| LTM Mar 2026 | -529.7% | +303.0 pp | -404.0 pp | |
| LTM Mar 2026 | -574.9% | -559.9 pp | -428.7 pp | |
| LTM Sep 2026 | -607.8% | -185.5 pp | +173259.4 pp | |
| FY2025 | -1218.0% | -106.2 pp | +17688.5 pp | |
| FY2025 | -1764.5% | -1372.5 pp | -1663.8 pp | |
| Peer median (excluding IMCR) | -458.0% | -79.1 pp | -4.9 pp | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 27.04M | 144.23M | 197.39M | 247.98M | 297.57M |
| Cost of Revenue | 0 | 5.29M | 820.63K | 5.54M | 6.21M |
| Gross Profit | 27.04M | 138.94M | 196.57M | 242.44M | 291.36M |
| Gross Margin | 100.0% | 96.3% | 99.6% | 97.8% | 97.9% |
| Research & Development | 74.31M | 84.31M | 129.42M | 177.44M | 204.47M |
| Selling, General & Admin | 82.15M | 0 | 114.35M | 121.17M | 120.62M |
| Operating Expenses | 156.46M | 181.71M | 243.77M | 298.77M | 325.09M |
| Depreciation & Amortization | 5.63M | 4.41M | 3.24M | 3.36M | 2.43M |
| EBITDA | (123.58M) | (38.35M) | (40.87M) | (38.5M) | 387.18K |
| EBITDA Margin | -457.0% | -26.6% | -20.7% | -15.5% | 0.1% |
| Operating Income | (129.42M) | (42.77M) | (47.2M) | (56.28M) | (33.74M) |
| Operating Margin | -478.5% | -29.7% | -23.9% | -22.7% | -11.3% |
| Interest Income | 65K | 3.76M | 14.23M | 25.62M | 16.48M |
| Interest Expense | 5.57M | 5.41M | 4.08M | 18.84M | 12.17M |
| Other Income / Expenses | (3.92M) | 8.95M | (982.07K) | 14.01M | 19.53M |
| Income Before Tax | (133.34M) | (33.82M) | (48.19M) | (42.32M) | (14.21M) |
| Pre-Tax Margin | -493.0% | -23.4% | -24.4% | -17.1% | -4.8% |
| Income Tax Expense | 111.19K | 9.65M | (4.43M) | (1.48M) | 12.21M |
| Net Income | (133.45M) | (43.46M) | (43.75M) | (40.81M) | (26.42M) |
| Net Margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
| EPS (Basic) | (3.13) | (0.95) | (0.89) | (1.02) | (0.53) |
| EPS (Diluted) | (3.00) | (0.95) | (0.89) | (1.02) | (0.53) |
| Weighted Avg Shares | 42.49M | 45.71M | 48.89M | 49.99M | 50.35M |
| Weighted Avg Shares (Diluted) | 43.86M | 45.71M | 48.89M | 49.99M | 50.35M |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.